After a period of uneven performance, the biotech IPO market is beginning to show signs of renewed momentum.
On Monday, radiopharmaceutical oncology biotech Aktis Oncology (AKTS) launched a $200 million IPO; two days later, the company upsized the deal by 50%, disclosing a $100 million anchor investment from partner Eli Lilly. Aktis will mark the first sizable IPO of 2026 and the first major biotech to...
To read the rest of the article, sign up for a free trial of IPO Pro, the platform that gives you all of the IPO information you need, all in one place.
